Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Feb 2016

Douglas Michael P, Ladabaum Uri, Pletcher Mark J, Marshall Deborah A, Phillips Kathryn A

Abstract excerpt

The American College of Medical Genetics and Genomics (ACMG) recommends that mutations in 56 genes for 24 conditions are clinically actionable and should be reported as secondary findings after whole-genome sequencing (WGS). Our aim was to identify published economic evaluations of detecting mutations in these genes among the general population or among targeted/high-risk populations and conditions and identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Genetic Diseases, Inborn

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic factors in colorectal cancer

Share to Genetic Testing

Share to Genetics, Medical

Share to Genome, Human

Share to Mutation

Share to Sequence Analysis, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 25996638
DOI: 10.1038/gim.2015.69
PMCID: PMC4654986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.PMID 25996638Read ↗

Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviewsSemantic proximity Read ↗

Genetic findings and health care utilization among individuals undergoing population genomic screening for actionable hereditary disorders.Semantic proximity Read ↗

Protocol for a Prospective, Observational Cost-effectiveness Analysis of Returning Secondary Findings of Genome Sequencing for Unexplained Suspected Genetic Conditions.Semantic proximity Read ↗

Report – Cost and Clinical Utility of WES and WGS in pediatric patients with suspected genetic diseaseSemantic proximity Read ↗

Economic evaluation of next-generation sequencing techniques in diagnosis of genetic disorders: A systematic review.Semantic proximity Read ↗

Identification of Medically Actionable Secondary Findings in the 1000 Genomes.Semantic proximity Read ↗

Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditionsSemantic proximity Read ↗

Genetic screening by DNA technology: a systematic review of health economic evidence.Semantic proximity Read ↗

Diagnostic yield of genetic screening in a diverse, community-ascertained cohortSemantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

The impact of clinical genome sequencing in a global population of patients with suspected rare genetic diseaseSemantic proximity Read ↗

Recommendations for returning genomic incidental findings? We need to talk!Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.